Matrix M is an immune stimulating substance for use in vaccines, antibody production and immunological research.
Matrix M was already licensed to Crucell for use in influenza vaccines, under an existing agreement.
The results from a Phase I clinical trial with Isconova’s Matrix M adjuvant in an avian influenza vaccine showed increased number of antibody secreting cells and polyfunctional CD4+ Th1 cells.
The vaccine met all set criteria and was well tolerated without any serious adverse events.
Isconova CEO Lena Soderstrom said Isconova’s Matrix M induces both antibody-mediated and cellular immune responses, making it particularly suitable for vaccines in a number of disease areas.
"We consider it a confirmation of the strengths of our product that Crucell has selected Matrix M for use in two additional vaccine areas," Soderstrom said.